A predictive algorithm for the management of anaemia in haemodialysis patients based on ESA pharmacodynamics: Better results for less work

Nephrology Dialysis Transplantation

Volumn 27, Issue 6, 2012, Pages 2425-2429

  Lines, Simon W ^a   Lindley, Elizabeth J ^a   Tattersall, James E ^a   Wright, Mark J ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Anaemia; Haemodialysis

Indexed keywords

ANTIANEMIC AGENT; FERRIC HYDROXIDE SUCROSE; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; AGED; ALGORITHM; ANEMIA; ARTICLE; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; PREDICTIVE ALGORITHM; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEADY STATE; TREATMENT OUTCOME;

ADULT; AGED; ALGORITHMS; ANEMIA; DISEASE MANAGEMENT; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; TISSUE DISTRIBUTION;

EID: 84861839186     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr706     Document Type: Article

References (21)

1. Fishbane S, Berns JS.Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005; 68: 1337-1343
2. Ebben JP, Gilbertson DT, Foley RN et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006; 1: 1205-1210
3. Will EJ, Richardson D, Tolman C et al. Development and exploitation of a clinical decision support system for the management of renal anaemia. Nephrol Dial Transplant 2007; 22 (Suppl. 4): iv31-iv36
4. Tolman C, Richardson D, Bartlett C et al. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol 2005; 16: 1463-1470
5. Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992; 51: 76-89
6. Kalicki RM, Uehlinger DE. Red cell survival in relation to changes in the hematocrit: more important than you think. Blood Purif 2008; 26: 355-360
7. Berns JS, Elzein H, Lynn RI et al. Hemoglobin variability in epoetintreated hemodialysis patients. Kidney Int 2003; 64: 1514-1521
8. Richardson D, Bartlett C, Will EJ. Intervention thresholds and ceilings can determine the haemoglobin outcome distribution in a haemodialysis population. Nephrol Dial Transplant 2000; 15: 2007-2013
9. National Institute for Health and Clinical Excellence 2006. Anaemia Management in Chronic Kidney Disease (Clinical Guideline 39). London: National Institute for Health and Clinical Excellence, 2006
10. National Institute for Health and Clinical Excellence 2011. Anaemia Management in People with Chronic Kidney Disease (Clinical Guideline 114). London: National Institute for Health and Clinical Excellence, 2011
11. Gaweda AE, Jacobs AA, Aronoff GR et al. Model predictive control of erythropoietin administration in the anemia of ESRD. Am J Kidney Dis 2008; 51: 71-79
12. Miskulin DC, Weiner DE, Tighiouart H et al. Computerized decision support for EPO dosing in hemodialysis patients. Am J Kidney Dis 2009; 54: 1081-1088
13. Ho WR, Germain MJ, Garb J et al. Use of 12x/month haemoglobin monitoring with a computer algorithm reduces haemoglobin variability. Nephrol Dial Transplant 2010; 25: 2710-2714
14. Fishbane S, Berns JS. Evidence and implications of haemoglobin cycling in anaemia management. Nephrol Dial Transplant 2007; 22: 2129-2132
15. Pisoni RL, Bragg-Gresham JL, Fuller DS et al. Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): associations with mortality, patient characteristics, and facility practices. Am J Kidney Dis 2011; 57: 266-275
16. Electronic Medicines Compendium. Summary of Product Characteristics for Aranesp (darbepoetin alfa). http://www.medicines.org.uk/EMC/medicine/4981/SPC/ ARANESP1PFS/(25 August 2011, date last accessed)
17. Lacson E Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003; 41: 111-124
18. Allon M, Kleinman K, Walczyk M et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther 2002; 72: 546-555
19. Lopez-Gomez JM, Portoles JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl 2008; 111: S75-S81
20. Gaweda AE, Nathanson BH, Jacobs AA et al. Determining optimum hemoglobin sampling for anemia management from every-treatment data. Clin J Am Soc Nephrol 2010; 5: 1939-1945
21. Brier ME, Gaweda AE, Dailey A et al. Randomized trial of model predictive control for improved anemia management. Clin J Am Soc Nephrol 2010; 5: 814-820